Navidea Biopharmaceuticals has patented a method for conjugating a metal chelating agent to a functionalized dextran by reacting a chelator with an aminated dextran backbone. The process ensures the complex is free of crosslinking, offering potential applications in medical imaging and drug delivery. GlobalData’s report on Navidea Biopharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Navidea Biopharmaceuticals Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Navidea Biopharmaceuticals, Isotropically modified heterocyclic compounds was a key innovation area identified from patents. Navidea Biopharmaceuticals's grant share as of February 2024 was 46%. Grant share is based on the ratio of number of grants to total number of patents.

Method for conjugating metal chelating agent to functionalized dextran

Source: United States Patent and Trademark Office (USPTO). Credit: Navidea Biopharmaceuticals Inc

A recently granted patent (Publication Number: US11859023B2) discloses a method for conjugating a metal chelating agent to a functionalized dextran. The process involves reacting a chelator with an aminated dextran backbone, where the chelator has carboxylic acid groups, with only one being activated to form a chelator-dextran complex. The dextran-chelator complex is ensured to be free of intra- or intermolecular crosslinking, enhancing its stability and effectiveness.

Furthermore, the patent details a method for synthesizing an amine dextran by adding mannose moieties to the chelator-dextran complex through amidate linkage to the dextran backbone. This innovative approach offers a versatile way to modify dextran for various applications. The protecting groups used in the process, such as t-butyl esters, play a crucial role in ensuring the success of the conjugation process, highlighting the importance of each step in the method outlined in the patent.

To know more about GlobalData’s detailed insights on Navidea Biopharmaceuticals, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies